A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma

Conclusions This study demonstrated the safety of nevanimibe at doses of up to ~6000  mg BID. As the total number of tablets required to achieve an MTD exceeded practical administration limits, a maximumfeasible dose was defined. Given that the expected exposure levels necessary for an apoptotic effect could not be achieved, the current formulation of nevanimibe had limited efficacy in patients with advanced ACC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Publication date: Available online 10 October 2020Source: European UrologyAuthor(s): Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: Available online 10 October 2020Source: Respiratory Medicine Case ReportsAuthor(s): Vipul Patel, Tilottama Majumdar, Isha Samreen, Harpreet Grewal, Thomas Kaleekal
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Authors: Peng C, Cohen DJ Abstract INTRODUCTION: Esophageal squamous cancer remains an important cause of mortality worldwide with two new immunotherapy drugs recently approved for metastatic disease. AREAS COVERED: The authors review the epidemiology and genomics of esophageal squamous cell carcinoma. They also examine prior trials involving targeted agents under investigation as well immunotherapies that have been approved and novel combinations. EXPERT OPINION: Great advances have been made in characterizing the molecular changes in esophageal carcinoma. However, relatively few drugs have shown benefit i...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: Available online 9 October 2020Source: Pathology - Research and PracticeAuthor(s): Borislav A. Alexiev, Farres Obeidin, Daniel N. Johnson, Brian S. Finkelman, Rebecca Prince, Shaan N. Somani, Esther Cheng, Sandeep Samant
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): William H. Walker, O. Hecmarie Meléndez-Fernández, Jordan L. Pascoe, Ning Zhang, A. Courtney DeVries
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
ConclusionWe consider that this technique is useful, however, we have to exercise care in malignant cases as the true-positive rate may be low.
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
ConclusionThe more invasive approach does not correlate to a better outcome. In selected cases, DR is an oncologically safe technique; EBR is still a valid option to treat advanced oral cancers
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
ConclusionsThe expression level of MALAT1 is closely related with progression of tongue SCC. Furthermore, MALAT1 can serve as an independent biomarker for prognostic evaluation of tongue SCC.
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
More News: Addison's Disease | Adrenal Insufficiency | Adrenocortical Carcinoma | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Gastroenterology | Investigational New Drugs | Oral Cancer | Study | Toxicology